Baxter International Inc ($BAX) filed a 10K annual report for 2010 recently so here's an update to my $BAX cash flow valuation posted January 27. This update incorporates the firm's year-end 2010 data. I believe $BAX is undervalued now at $52/share and fairly valued at $61/share on a cash flow valuation basis.
Baxter International focuses on delivering injectable therapies for a wide variety of medical conditions. The firm's BioScience segment specializes in developing treatments for disorders such as hemophilia and immune deficiencies. It also provides a variety of medication delivery systems including intravenous bags, solutions, and other devices to control fluid inflow, including dialysis equipment and solutions for patients with kidney failure